drugset

drugset / Trial / NCT00036283

Chemoprevention of Oral Premalignant Lesions

NCT00036283 ↗

Phase 2 Completed 42 enrolled Pfizer

RandomizedParallel-groupDouble-blindPrevention

Summary

Reduction in size and number of oral premalignant lesions

Timeline

Start: 2000-11
Primary completion: —
Completion: 2004-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	—	—

Indications